CoChat
Sign Up
Cited by 329Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsMedical Imaging Techniques and Applications

Appropriate Use Criteria for Amyloid PET: A Report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association

Open access
Johnson, Keith A., Minoshima, Satoshi, Bohnen, Nicolaas I., Donohoe, Kevin J., Foster, Norman L., Herscovitch, Peter, Karlawish, Jason H., Rowe, Christopher C. +5 more·2013·Journal of Nuclear Medicine
DOI 10.2967/jnumed.113.120618
Open this paper in CoChat — free accountOpen PDF

Abstract

Positron emission tomography (PET) of brain amyloid β is a technology that is becoming more available, but its clinical utility in medical practice requires careful definition. To provide guidance to dementia care practitioners, patients, and caregivers, the Alzheimer's Association and the Society of Nuclear Medicine and Molecular Imaging convened the Amyloid Imaging Taskforce (AIT). The AIT considered a broad range of specific clinical scenarios in which amyloid PET could potentially be used appropriately. Peer-reviewed, published literature was searched to ascertain available evidence relevant to these scenarios, and the AIT developed a consensus of expert opinion. Although empirical evidence of impact on clinical outcomes is not yet available, a set of specific appropriate use criteria (AUC) were agreed on that define the types of patients and clinical circumstances in which amyloid PET could be used. Both appropriate and inappropriate uses were considered and formulated, and are reported and discussed here. Because both dementia care and amyloid PET technology are in active development, these AUC will require periodic reassessment. Future research directions are also outlined, including diagnostic utility and patient-centered outcomes.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2967/jnumed.113.120618

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The presence of Aβ pathology can be determined by PET or CSF assays measuring Aβ42/40, p-tau or total tau.

    “The presence of Aβ pathology can be determined by positron emission tomography (PET), which visualizes Aβ deposition in the brain, or cerebrospinal fluid (CSF) assays, which measure CSF levels of Aβ42 as a ratio with Aβ40, phosphorylated tau (p-tau) or total tau4,9–11.”

    From Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests (2024) · cites this paper as [10]

    Section 11.2 says that CSF measures of amyloid peptides and tau have been investigated to establish the presence of Alzheimer’s pathology; the paper also addresses amyloid PET as an imaging method. It does not specify an Aβ42/Aβ40 ratio or distinguish phosphorylated from total tau as the citing sentence does. The indexed passage has no page number. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 67

  1. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol 2004;55:306-19.
  2. Langa KM, Foster NL, Larson EB. Mixed dementia: emerging concepts and therapeutic implications. JAMA 2004;292:2901-8.
  3. Patel MR, Spertus JA, Brindis RG, Hendel RC, Douglas PS, Peterson ED, et al. ACCF proposed method for evaluating the appropriateness of cardiovas- cular imaging. J Am Coll Cardiol 2005;46:1606-13.
  4. Fryback DG, Thornbury JR. The efficacy of diagnostic imaging. Med Decision Making 1991;11:88-94. *
  5. Landau SM, Mintun MA, Joshi AD, Koeppe RA, Petersen RC, Aisen PS, et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol 2012;72:578-86.
  6. Johnson KA, Sperling RA, Gidicsin C, Carmasin J, Maye JE, Coleman RE, et al. Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease de- mentia, mild cognitive impairment, and normal aging. Alzheimers Dement In press.
  7. Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger- Gateau P, et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 2010;9:1118-27.
  8. Klunk WE. Amyloid imaging as a biomarker for cerebral beta-amyloidosis and risk prediction for Alzheimer dementia. Neurobiol Aging 2011;32:S20-36.
  9. Laforce R Jr, Rabinovici GD. Amyloid imaging in the differential diagnosis of dementia: review and potential clinical applications. Alzheimers Res Ther 2011;3:31. *
  10. Bacskai BJ, Frosch MP, Freeman SH, Raymond SB, Augustinack JC, Johnson KA, et al. Molecular imaging with Pittsburgh compound B confirmed at autopsy: a case report. Arch Neurol 2007;64:431-4. *
  11. Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, et al. Post-mortem correlates of in vivo PiB-PET amyloid im- aging in a typical case of Alzheimer's disease. Brain 2008;131:1630-45. *
  12. Cairns NJ, Ikonomovic MD, Benzinger T, Storandt M, Fagan AM, Shah AR, et al. Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. Arch Neurol 2009;66:1557-62. *
  13. Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study. Lancet Neurol 2012;11:669-78. *
  14. Doraiswamy PM, Sperling RA, Coleman RE, Johnson KA, Reiman EM, Davis MD, et al. Amyloid-beta assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology 2012;79:1636-44. *
  15. Jack CR Jr, Wiste HJ, Vemuri P, Weigand SD, Senjem ML, Zeng G, et al. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain 2010;133:3336-48. *
  16. Koivunen J, Pirttila T, Kemppainen N, Aalto S, Herukka SK, Jauhianen AM, et al. PET amyloid ligand [11C]PIB uptake and cerebrospinal fluid beta-amyloid in mild cognitive impairment. Dement Geriatr Cogn Disord 2008;26:378-83. *
  17. Okello A, Koivunen J, Edison P, Archer HA, Turkheimer FE, Nagren K, et al. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C- PIB PET study. Neurology 2009;73:754-60. *
  18. Rabinovici GD, Rosen HJ, Alkalay A, Kornak J, Furst AJ, Agarwal N, et al. Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurol- ogy 2011;77:2034-42. *
  19. Sojkova J, Driscoll I, Iacono D, Zhou Y, Codispoti KE, Kraut MA, et al. In vivo fibrillar beta-amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults. Arch Neurol 2011;68:232-40. *
  20. Wolk DA, Price JC, Saxton JA, Snitz BE, James JA, Lopez OL, et al. Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol 2009;65:557-68. *
  21. Wolk DA, Grachev ID, Buckley C, Kazi H, Grady MS, Trojanowski JQ, et al. Association between in vivo fluorine 18-labeled flutemetamol amyloid posi- tron emission tomography imaging and in vivo cerebral cortical histopathol- ogy. Arch Neurol 2011;68:1398-403. *
  22. Villain N, Chetelat G, Grassiot B, Bourgeat P, Jones G, Ellis KA, et al. Re- gional dynamics of amyloid-beta deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study. Brain 2012;135:2126-39. *
  23. Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, et al. PET imaging of amyloid deposition in patients with mild cognitive impair- ment. Neurobiol Aging 2008;29:1456-65. *
  24. Foster ER, Campbell MC, Burack MA, Hartlein J, Flores HP, Cairns NJ, et al. Amyloid imaging of Lewy body-associated disorders. Mov Disord 2010;25:2516-23. *
  25. Kepe V, Ghetti B, Farlow MR, Bresjanac M, Miller K, Huang SC, et al. PET of brain prion protein amyloid in Gerstmann-Straussler-Scheinker disease. Brain Pathol 2010;20:419-30. *
  26. Villemagne VL, McLean CA, Reardon K, Boyd A, Lewis V, Klug G, et al. 11C-PiB PET studies in typical sporadic Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 2009;80:998-1001. *
  27. Jagust WJ, Bandy D, Chen K, Foster NL, Landau SM, Mathis CA, et al. The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement 2010;6:221-9. *
  28. Johnson KA, Gregas M, Becker JA, Kinnecom C, Salat DH, Moran EK, et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol 2007;62:229-34. *
  29. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007;6:734-46.
  30. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004;256:183-94.
  31. Petersen RC. Mild cognitive impairment or questionable dementia? Arch Neu- rol 2000;57:643-4.
  32. Morris JC. Revised criteria for mild cognitive impairment may compromise the diagnosis of Alzheimer disease dementia. Arch Neurol 2012;69:700-8.
  33. Ossenkoppele R, Tolboom N, Foster-Dingley JC, Adriaanse SF, Boellaard R, Yaqub M, et al. Longitudinal imaging of Alzheimer pathology using [11C] PIB, [18F]FDDNP and [18F]FDG PET. Eur J Nucl Med Mol Imaging 2012;39:990-1000.
  34. Wey SP, Weng CC, Lin KJ, Yao CH, Yen TC, Kung HF, et al. Validation of an (18)F-labeled biphenylalkyne as a positron emission tomography imaging agent for beta-amyloid plaques. Nucl Med Biol 2009;36:411-7.
  35. Fodero-Tavoletti MT, Mulligan RS, Okamura N, Furumoto S, Rowe CC, Kudo Y, et al. In vitro characterisation of BF227 binding to alpha-synuclein/ Lewy bodies. Eur J Pharmacol 2009;617:54-8.
  36. Henriksen G, Yousefi BH, Drzezga A, Wester HJ. Development and evaluation of compounds for imaging of beta-amyloid plaque by means of positron emis- sion tomography. Eur J Nucl Med Mol Imaging 2008;35:S75-81.
  37. Burack MA, Hartlein J, Flores HP, Taylor-Reinwald L, Perlmutter JS, Cairns NJ. In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia. Neurology 2010;74:77-84.
  38. Kadir A, Marutle A, Gonzalez G, Scholl M, Almkvist O, Mousavi M, et al. Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh compound B positron emission tomography patient with Alzheimer's disease. Brain 2011;134:301-17.
  39. Kantarci K, Yang C, Schneider JA, Senjem ML, Reyes DA, Lowe VJ, et al. Ante mortem amyloid imaging and beta-amyloid pathology in a case with dementia with Lewy bodies. Neurobiol Aging 2012;33:878-85.
  40. Ikonomovic MD, Abrahamson EE, Price JC, Hamilton RL, Mathis CA, Paljug WR, et al. Early AD pathology in a [C-11]PiB-negative case: a PiB- amyloid imaging, biochemical, and immunohistochemical study. Acta Neuro- pathol 2012;123:433-47.
  41. Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol 2010;68:319-29.
  42. Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O'Keefe G, et al. Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 2008;7:129-35.
  43. Vallabhajosula S. Positron emission tomography radiopharmaceuticals for im- aging brain beta-amyloid. Semin Nucl Med 2011;41:283-99.
  44. Cselenyi Z, Jonhagen ME, Forsberg A, Halldin C, Julin P, Schou M, et al. Clinical validation of 18F-AZD4694, an amyloid-beta-specific PET radioli- gand. J Nucl Med 2012;53:415-24.
  45. Jureus A, Swahn BM, Sandell J, Jeppsson F, Johnson AE, Johnstrom P, et al. Characterization of AZD4694, a novel fluorinated Abeta plaque neuroimaging PET radioligand. J Neurochem 2010;114:784-94.
  46. Rowe CC, Pejoska S, Mulligan RS, Gareth Jones G, Chan JG, Svensson S, et al. Head to head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for Ab imaging in ageing and dementia. J Nucl Med In press.
  47. Rinne JO, Wong DF, Wolk DA, Leinonen V, Arnold SE, Buckley C, et al. [(18) F]Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid beta detection in living subjects with normal pressure hydrocephalus: pooled analysis of four studies. Acta Neuropathol 2012;124:833-45.
  48. Wolk DA, Zhang Z, Boudhar S, Clark CM, Pontecorvo MJ, Arnold SE. Amyloid imaging in Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography. J Neurol Neurosurg Psychiatry 2012;83:923-6.
  49. Landau SM, Breault C, Joshi AD, Pontecorvo M, Mathis CA, Jagust WJ, et al. Amyloid-beta imaging with Pittsburgh compound B and florbetapir: compar- ing radiotracers and quantification methods. J Nucl Med 2013;54:70-7.
  50. Villemagne VL, Mulligan RS, Pejoska S, Ong K, Jones G, O'Keefe G, et al. Comparison of 11C-PiB and 18F-florbetaben for Abeta imaging in ageing and Alzheimer's disease. Eur J Nucl Med Mol Imaging 2012;39:983-9.
  51. Foster NL, Heidebrink JL, Clark CM, Jagust WJ, Arnold SE, Barbas NR, et al. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain 2007;130:2616-35.
  52. Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, et al. Am- yloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 2010;31:1275-83.
  53. Gomperts SN, Rentz DM, Moran E, Becker JA, Locascio JJ, Klunk WE, et al. Imaging amyloid deposition in Lewy body diseases. Neurology 2008;71: 903-10.
  54. Edison P, Rowe CC, Rinne JO, Ng S, Ahmed I, Kemppainen N, et al. Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry 2008;79:1331-8.
  55. Greenberg SM, Grabowski T, Gurol ME, Skehan ME, Nandigam RN, Becker JA, et al. Detection of isolated cerebrovascular beta-amyloid with Pittsburgh compound B. Ann Neurol 2008;64:587-91.
  56. Haglund M, Sjobeck M, Englund E. Severe cerebral amyloid angiopathy char- acterizes an underestimated variant of vascular dementia. Dement Geriatr Cogn Disord 2004;18:132-7.
  57. Ly JV, Rowe CC, Villemagne VL, Zavala JA, Ma H, O'Keefe G, et al. Cerebral beta-amyloid detected by Pittsburgh compound B positron emission topogra- phy predisposes to recombinant tissue plasminogen activator-related hemor- rhage. Ann Neurol 2010;68:959-62.
  58. Gurol ME, Viswanathan A, Gidicsin C, Hedden T, Martinez SR, Dumas A, et al. Cerebral amyloid angiopathy burden associated with leukoaraiosis: a PET/MRI study. Ann Neurol In press.
  59. Tomiyama T, Nagata T, Shimada H, Teraoka R, Fukushima A, Kanemitsu H, et al. A new amyloid beta variant favoring oligomerization in Alzheimer's- type dementia. Ann Neurol 2008;63:377-87.
  60. Roman GC, Wilkinson DG, Doody RS, Black SE, Salloway SP, Schindler RJ. Donepezil in vascular dementia: combined analysis of two large-scale clinical trials. Dement Geriatr Cogn Disord 2005;20:338-44.
  61. Blendon RJ, Benson JM, Wikler EM, Weldon KJ, Georges J, Baumgart M, et al. The impact of experience with a family member with Alzheimer's disease on views about the disease across five countries. Int J Alzheimers Dis 2012. In press.
  62. Choo IH, Ni R, Scholl M, Wall A, Almkvist O, Nordberg A. Combination of 18F-FDG PET and cerebrospinal fluid biomarkers as a better predictor of the progression to Alzheimer's disease in mild cognitive impairment patients. J Alzheimers Dis. In press.
  63. Ioannidis JP, Panagiotou OA. Comparison of effect sizes associated with bio- markers reported in highly cited individual articles and in subsequent meta- analyses. JAMA 2011;305:2200-10.
  64. Herholz K, Carter SF, Jones M. Positron emission tomography imaging in dementia. Br J Radiol 2007;80:S160-7.
  65. Bohnen NI, Minoshima S. FDG-PET and molecular brain imaging in the movement disorders clinic. Neurology 2012;79:1306-7.
  66. Fagan AM, Head D, Shah AR, Marcus D, Mintun M, Morris JC, et al. De- creased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cogni- tively normal elderly. Ann Neurol 2009;65:176-83.
  67. Burke JF, Albin RL, Koeppe RA, Giordani B, Kilbourn MR, Gilman S, et al. Assessment of mild dementia with amyloid and dopamine terminal positron emission tomography. Brain 2011;134:1647-57.

Cited by

Sorted by citations

Authors
Johnson, K. A., Minoshima, S., Bohnen, N. I., Donohoe, K. J., Foster, N. L., Herscovitch, P., Karlawish, J. H., Rowe, C. C., Carrillo, M. C., Hartley, D. M., Hedrick, S., Pappas, V., & Thies, W. H.
Affiliations
  • Harvard University (US)
  • University of Washington (US)
  • University of Michigan (US)
  • Beth Israel Deaconess Medical Center (US)
  • University of Utah (US)
  • National Institutes of Health (US)
  • University of Pennsylvania (US)
  • The University of Melbourne (AU)
  • Alzheimer's Association (US)
  • Society of Nuclear Medicine and Molecular Imaging (US)
ORCID
Venue
Journal of Nuclear Medicine
Publisher
Society of Nuclear Medicine
Published
2013-01-28
Volume
54
Issue
3
Pages
476-490
ISSN
  • 0161-5505 (ISSN-L)
  • 2159-662X
DOI
10.2967/jnumed.113.120618
OpenAlex
W2028943878
Cited by
329
References
12
Citations by year
2026: 18 · 2025: 16 · 2024: 20 · 2023: 15 · 2022: 20 · 2021: 25 · 2020: 28 · 2019: 37 · 2018: 18 · 2017: 33 · 2016: 33 · 2015: 25 · 2014: 18 · 2013: 22
FWCI
23.23
Type
journal article
Language
en
Open access
Locations
  • Journal of Nuclear Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Keywords
amyloid PET, brain amyloid-beta, appropriate use criteria, Alzheimer's disease, dementia, amyloid imaging, clinical utility, expert consensus, diagnostic value, patient-centered outcomes
MeSH terms
Alzheimer Disease, Brain, Carbon Radioisotopes, Humans, Nuclear Medicine, Societies, Medical, Amyloid beta-Peptides, Radiopharmaceuticals, Evidence-Based Medicine, Advisory Committees, Positron-Emission Tomography, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review